InvestorsHub Logo
Followers 2
Posts 319
Boards Moderated 0
Alias Born 08/29/2018

Re: None

Wednesday, 01/27/2021 4:57:10 PM

Wednesday, January 27, 2021 4:57:10 PM

Post# of 27409
Endotoxin removal remains front and center. What ever happened to our Sorb XL product? I hope it will be discussed in the upcoming shareholder letter. It sure looks more and more like endotoxin is a primary trigger of sepsis and the subsequent cytokine storm. I am certain I don't have to remind other shareholders of our letter dated August 2016 that claimed our XL product would, "for all intents and purposes", make other more proven endotoxin filters obsolete. Don't we have to run a trial or provide some sort of actual usage and efficacy around the shiny new filter? I don't think a planted Q&A session inside a competitor's AGM is enough to get this hidden gem across the finish line but I may be wrong. Anyone know if it has been used yet, at least on a human and not just on the lab bench. Their IR guy had told me a long time ago that it was being used in REHASH II, but that turned out to be incorrect intel. I can't wait to see this unleashed in a nice 500 patient RCT trial that leaves the competition in our endotoxic dust! Bring on the XL and bring on the BIG profits!!!!!!!
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CTSO News